Financial Performance - The company's operating revenue for the first half of 2023 was CNY 567.32 million, representing a 13.58% increase compared to CNY 499.49 million in the same period last year[20]. - The net profit attributable to shareholders of the listed company reached CNY 168.55 million, a significant increase of 2,057.82% from a loss of CNY 8.61 million in the previous year[20]. - The net cash flow from operating activities improved to CNY 13.87 million, a 164.97% increase from a negative cash flow of CNY 21.35 million in the same period last year[20]. - The basic earnings per share rose to CNY 0.1819, compared to a loss of CNY 0.0093 per share in the previous year, marking a 2,055.91% increase[20]. - The total profit for the first half of 2023 was CNY 178,386,065.81, compared to a loss of CNY 15,616,341.67 in the same period last year[155]. - The company reported a net loss of CNY 155,105,758.00 for the first half of 2023, an improvement from a net loss of CNY 323,650,790.01 in the same period of 2022[152]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2.43 billion, a decrease of 2.33% from CNY 2.49 billion at the end of the previous year[20]. - The total liabilities decreased to RMB 1,200,000,000.00, down from RMB 1,250,000,000.00, reflecting a reduction of 4%[148]. - The total assets as of June 30, 2023, amounted to CNY 2,380,240,176.00, slightly down from CNY 2,387,433,939.06 at the beginning of the year[152]. - The total equity of the company as of June 30, 2023, was RMB 1,232,362,399.27, down from RMB 1,240,346,685.37 at the beginning of the year[148]. Revenue Breakdown - In the first half of 2023, the company's ceramic tile business achieved revenue of 478 million yuan, a year-on-year increase of 15%, despite the overall domestic ceramic tile production declining by 15.10%[39]. - Tile sales contributed CNY 478 million, accounting for 84.4% of total revenue, with a growth of 15.24% year-on-year[48]. - The health and wellness (care/medical) business generated CNY 45 million, with a year-on-year increase of 6.47%[48]. - The company's revenue for the reporting period reached ¥567,322,497.67, representing a year-on-year increase of 13.58%, primarily driven by a 16% rise in tile sales revenue due to enhanced project follow-up and distribution channel layout[53]. Investment and Acquisitions - The company has no plans for major acquisitions or new product launches announced during this reporting period[4]. - The company is exploring potential mergers and acquisitions to bolster its market share and diversify its product offerings[167]. - The company transferred control of its subsidiary to reduce operational risks and secure funding for land development projects[47]. Research and Development - Research and development expenses amounted to ¥17,140,747.30, up 16.05% year-on-year, attributed to increased small-scale trial costs[53]. - The company launched 23 new products in the first half of 2023, with new product sales accounting for 18% of total revenue[41]. - Research and development expenses for the first half of 2023 were approximately 73 million yuan, representing an increase of 35% year-on-year[171]. Market Strategy - The company is actively expanding its market presence, with a focus on both domestic and international sales channels, including e-commerce and direct sales[31]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[154]. - The company is focusing on maintaining its competitive edge in the healthcare sector amidst potential policy changes and market competition[74]. Environmental and Social Responsibility - The company has invested RMB 2.1088 million in environmental governance and protection in the first half of 2023[92]. - The company has established a zero discharge policy for industrial wastewater, utilizing two large wastewater treatment stations[90]. - The company’s emissions of smoke and pollutants are compliant with the relevant standards, with specific measures in place for dust and wastewater treatment[90]. Shareholder Information - The company will not distribute cash dividends or bonus shares for the half-year period[79]. - The total number of shareholders at the end of the reporting period is 73,702[133]. - CIMIC Industrial Inc. holds 37.41% of the shares, totaling 346,631,164 shares, with a decrease of 16,105,000 shares during the reporting period[133]. Governance and Compliance - The company has established a robust governance framework to support its growth and ensure compliance with regulatory requirements[179]. - The financial statements are prepared based on the going concern principle, confirming the company's ability to continue operations for at least the next 12 months[188]. - The company has not reported any new product launches or technological advancements in this period[174].

上海悦心健康集团股份有限公司 独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的 专项说明和独立意见 根据《上市公司独立董事规则》、《深圳证券交易所股票上市规则》、《深圳证券交易 所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关法律、法规和规范 性文件以及《公司章程》等规定和要求，作为上海悦心健康集团股份有限公司（以下简 称"公司"）的独立董事，基于独立判断立场，我们对 2023 年半年度（以下简称"报告 期"）公司对外担保、公司控股股东及其他关联方占用公司资金等情况进行了认真细致 的核查，发表如下专项说明和独立意见： 一、关于公司对外担保情况的专项说明及独立意见 根据《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》， 我们对公司累计和当期对外担保情况进行了仔细的核查，发表专项说明和独立意见如 下： 1、报告期内，公司对外提供担保均已按照有关法律、法规及《公司章程》的规定履行 了相关审议程序，不存在违规担保情况。 根据《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》， 我们对公司与控股股东及其他关联方的资金往来进行了仔细的核查，发表专项 ...

2023年半年度非经营性资金占用及其他关联资金往来情况汇总表 附件一 企业负责人： 主管会计工作的负责人： 会计机构负责人： | 上市公司名称：上海悦心健康集团股份有限公司 | | | | | | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 占用方与上市公司的关联 | 上市公司核算的 | 2023年期初占 | 2023年1-6月占用累计发 | 2023年1-6月占用 | 2023年1-6月偿还累计 | 2023年6月30日 | | | | | 非经营性资金占用 | 资金占用方名称 | 关系 | 会计科目 | 用资金余额 | 生金额(不含利息） | 资金的利息 | 发生金额 | 占用资金余额 | | 占用形成原因 | 占用性质 | | 控股股东、实际控制人及其附 | | | | | | | | | | | | | 属企业 | | | | | | | | | | | | | 小计 | - | - | - | - | - | - | - | | - | - | - ...

证券代码：002162 证券简称：悦心健康 上海悦心健康集团股份有限公司投资者关系活动记录表 编号：202302 | --- | --- | --- | |--------------------|----------------------------------------------------------|----------------------------------| | 投资者关系活动类别 | √特定对象调研 □分析师会议□媒体采访 □新闻发布会 □路演活动 | □业绩说明会 | | | □现场参观 | □其他 （请文字说明其他活动内容） | 活动参与人员 华西证券 许光辉 时间 2023 年 6 月 27 日 15:00-16:30 地点 上海市闵行区浦江镇恒南路 1288 号公司会议室 | --- | --- | |-------------------------|-------| | 副总裁 何志明 | | | 董事会秘书 程 | 梅 | | 金海悦心颐养院负责人 王 | 璐 | | 证券事务代表 莫丹丹 | | 上市公司接待 人员 形式 现场会议 一、公司基本情况介绍 公司上半年瓷 ...

Financial Performance - The company's revenue for Q1 2023 was ¥221,065,012.52, representing an increase of 18.52% compared to ¥186,519,515.45 in the same period last year[5] - The net profit attributable to shareholders was -¥7,672,898.23, an improvement of 49.83% from -¥15,294,690.85 year-on-year[5] - The net cash flow from operating activities improved by 55.51%, reaching -¥43,674,374.02 compared to -¥98,177,017.43 in Q1 2022[13] - The company reported a 288.99% increase in investment income, amounting to ¥2,208,237.86, primarily due to dividends received from an associate[11] - The gross profit from tile sales increased by approximately 22% year-on-year, contributing an additional ¥5,500,000 to gross profit[12] - Total operating revenue for Q1 2023 was CNY 221,065,012.52, an increase of 18.5% compared to CNY 186,519,515.45 in the same period last year[20] - Net loss for Q1 2023 was CNY 7,679,632.24, compared to a net loss of CNY 15,314,285.60 in Q1 2022, representing a 50.2% improvement[22] - Basic and diluted earnings per share for Q1 2023 were both CNY -0.0083, an improvement from CNY -0.0165 in Q1 2022[22] Cash Flow - The net cash flow from financing activities significantly increased by 290.91%, reaching ¥72,231,449.31 compared to -¥37,836,020.70 in the same period last year[13] - The net cash flow from operating activities increased year-on-year due to higher sales receipts[15] - The net cash flow from investing activities increased year-on-year due to government compensation received for land[15] - Cash inflow from operating activities totaled CNY 303,136,419.50, compared to CNY 258,874,466.32 in the same period last year, reflecting a growth of 17.1%[23] - The total cash and cash equivalents at the end of the period amounted to ¥165,799,949.86, an increase from ¥141,167,358.41 at the beginning of the period[24] - The company experienced a net increase in cash and cash equivalents of ¥24,632,591.45, contrasting with a decrease of -¥149,926,772.02 in the previous period[24] - The company received cash from borrowings totaling ¥100,000,000.00[24] - The company distributed dividends and interest payments totaling ¥8,485,965.13[24] Assets and Liabilities - Total assets decreased by 2.38% to ¥2,431,037,643.33 from ¥2,490,346,685.37 at the end of the previous year[5] - The total assets amounted to 2,431,037,643.33 yuan, a decrease from 2,490,346,685.37 yuan at the beginning of the year[18] - Current liabilities totaled 902,864,858.04 yuan, down from 953,990,135.67 yuan at the beginning of the year[18] - The company's long-term borrowings were 300,000,000 yuan, slightly down from 303,750,000 yuan at the beginning of the year[18] - The total liabilities were 1,407,361,703.10 yuan, a decrease from 1,473,317,979.11 yuan at the beginning of the year[18] - The company's capital reserve increased to 196,283,288.37 yuan from 195,436,092.77 yuan at the beginning of the year[18] - The company reported a total of 898,448,318.05 yuan in current assets, down from 942,685,963.79 yuan at the beginning of the year[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 71,020, with no preferred shareholders having restored voting rights[14] - CIMIC INDUSTRIAL INC. holds 38.41% of shares, amounting to 355,896,164 shares, with 100 million shares pledged[14] Research and Development - The company received government subsidies of ¥166,563.40 related to R&D investments during the reporting period[6] - Research and development expenses for Q1 2023 were CNY 1,768,801.66, a decrease of 19.9% from CNY 2,210,031.22 in the same period last year[20] Other Information - The company established a new non-wholly-owned subsidiary, resulting in a 124.75% increase in minority interests to ¥24,254,863.72[9] - The impact of exchange rate changes on cash and cash equivalents was a decrease of -¥11,112.98[24] - The company did not undergo an audit for the first quarter report[25] - The report was presented by the board of directors on April 26, 2023[26]

Financial Performance - The company's operating revenue for 2022 was ¥1,162,627,690.56, a decrease of 7.79% compared to ¥1,260,831,976.72 in 2021[26]. - The net profit attributable to shareholders was -¥278,424,533.43, representing a decline of 703.03% from a profit of ¥46,171,031.16 in the previous year[26]. - The cash flow from operating activities was ¥25,876,824.30, down 83.11% from ¥153,243,763.30 in 2021[26]. - The basic and diluted earnings per share were both -¥0.3005, a decrease of 679.00% compared to ¥0.0519 in 2021[26]. - Total assets at the end of 2022 were ¥2,490,346,685.37, an 8.20% decrease from ¥2,712,784,671.26 at the end of 2021[26]. - The net assets attributable to shareholders decreased by 21.30% to ¥1,006,236,659.41 from ¥1,278,519,957.81 in 2021[26]. - The company reported a significant loss from non-operating activities, with a total of -¥59,256,254.79 in 2022 compared to a gain of ¥17,399,019.11 in 2021[32]. - The company faced uncertainty regarding its ability to continue as a going concern, as indicated by the negative net profit for the last three accounting years[26]. Business Operations - The company has undergone changes in its business scope, now including health management consulting and medical enterprise management consulting[24]. - The company has no changes in its controlling shareholders[24]. - The company’s financial report is guaranteed to be true, accurate, and complete by its management team, including the CEO and accounting heads[4]. - The company operates a comprehensive procurement, production, and sales system, with a centralized procurement model and long-term contracts with key suppliers[47]. - The company has developed three main product lines in the health and wellness sector, focusing on vibrant seniors and specialized care for those with dementia or disabilities[51]. - The company has invested in various medical institutions, including hospitals and clinics, to expand its healthcare services[53]. - The company’s investment properties cover approximately 150,000 square meters in Shanghai, primarily leased to logistics companies[54]. - The company is actively responding to government policies on energy-intensive industries, achieving multiple indicators that meet national standards for energy conservation and emissions reduction[39]. Market Trends and Challenges - The real estate development investment in China decreased by 10% in 2022, reflecting broader industry challenges that may impact the company's performance[36]. - The company's tile business revenue was 974 million yuan, a year-on-year decrease of 10.61%, aligning with the overall industry trend[37]. - The actual production of ceramic tiles in 2022 was approximately 7.3 billion square meters, a year-on-year decline of 10.5%, with a capacity utilization rate of about 73%[37]. - The construction materials industry saw a revenue decline of 4.2% and a profit drop of 20.4% year-on-year in 2022, indicating a worsening trend[37]. - The prices of key raw materials and energy sources, such as natural gas and various minerals, have significantly increased, impacting production costs[44]. - The company faces risks from energy conservation policies, as the building ceramics industry is classified as a heavily polluting sector, necessitating ongoing investment in energy-saving technologies[112]. - Rising prices of raw materials and energy pose a risk to profit margins, with the company implementing annual procurement plans to mitigate cost increases[112]. Product Development and Innovation - In 2022, the company launched new large-format glass-ceramic products, including "Colorful Gem," "Golden Cave Stone," and "Morandi Series," enhancing product quality with features like high strength and low water absorption[46]. - The company is developing a new series of large-format polished tiles aimed at high-end retail markets, with a goal of achieving a good yield rate of over 85%[81]. - The introduction of new product lines, such as the "skin glaze" series, aligns with current market trends and enhances the company's brand image[83]. - The company launched over 40 new products in 2022, with new product sales accounting for nearly 18% of total revenue[57]. Strategic Initiatives - The company is planning to transform its 560 acres of industrial land into an innovative industrial cluster focused on smart medical research and development[64]. - The company is developing a vocational school in Wenzhou to train professionals in the health and wellness sector, expected to open in September 2023[62]. - The company is focusing on expanding its market presence in county and town markets, targeting new growth areas following urban renovation initiatives[109]. - The company aims to expand its channels for old community renovations and elderly-friendly modifications, capitalizing on government initiatives for urban renewal[108]. - The company is committed to promoting customized marketing strategies to enhance product value and meet user demands[109]. Management and Governance - The company has maintained a stable management team, with no significant changes in senior management roles during the reporting period[123]. - The company’s board of directors includes members with extensive backgrounds in finance and management, enhancing its strategic decision-making capabilities[125][126][127][128]. - The company’s financial leadership includes a CFO with experience in both auditing and financial management, contributing to robust financial oversight[126]. - The company has established a governance structure with a board of directors, supervisory board, and various committees to ensure effective decision-making and oversight[158]. - The company’s independent directors have been in place since 2017, ensuring governance and oversight[123]. Environmental Responsibility - The company has a valid pollution discharge permit effective until October 16, 2027, ensuring compliance with environmental regulations[165]. - The company has implemented measures to manage and control environmental factors related to its production activities, ensuring compliance with pollution discharge standards[164]. - Jiangxi Smick's total emissions for smoke dust were 3.473 tons, well below the approved limit of 31.24 tons per year, achieving compliance[166]. - Jiangxi Smick's SO2 emissions were 25.869 tons, significantly under the approved limit of 35.21 tons per year, also meeting standards[166]. - Jiangxi Smick's NOX emissions reached 51.052 tons, well within the approved limit of 105.36 tons per year, indicating compliance[166]. - The company has implemented a comprehensive environmental management system, certified by a third party, ensuring ongoing compliance and transparency[176]. Employee Development - The total number of employees at the end of the reporting period was 920, with 622 from the parent company and 298 from major subsidiaries[150]. - The company conducted a total of 16 training sessions in 2022, enhancing employee skills and supporting distributors[153]. - The company organized nearly 30 training sessions related to elderly care business, with over 400 participants[153]. - The company emphasizes performance management and salary optimization to align employee compensation with company development[151].

（问题征集专题页面二维码） 本公司及董事会全体成员保证公告内容的真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 上海悦心健康集团股份有限公司（以下简称"公司"）于 2023 年 3 月 18 日披 露了《2022 年年度报告全文及摘要》。为便于广大投资者进一步了解公司的经营 情况，公司定于 2023 年 3 月 23 日（星期四）15:00－17:00 举办 2022 年度业绩说 明会。本次年度业绩说明会将采用网络远程的方式举行，投资者可登陆全景网"投 资者关系互动平台"（http://ir.p5w.net）参与本次年度业绩说明会。 出席本次业绩说明会的人员有董事长李慈雄先生、总裁余璟先生、财务负责人 赵一非先生、董事会秘书程梅女士、独立董事唐松莲女士。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 3 月 22 日（星期三）17:00 前访问全景网（http://ir.p5w.net/zj/）或扫描下方二维 码，进入问题征集专题页面。公司将在 2022 年度业绩说明会上，对投资者普遍关 注 ...